Used primarily in cancer research, this compound acts as a potent inhibitor of checkpoint kinases Chk1 and Chk2. It enhances the effectiveness of DNA-damaging agents such as chemotherapy and radiation by preventing cancer cells from repairing DNA damage, leading to increased cell death. It has been studied in preclinical models for various solid tumors and hematological malignancies, often in combination with other anticancer drugs. Its ability to abrogate cell cycle checkpoints makes it a candidate for overcoming treatment resistance in tumors with defective p53 pathways. Research use only; not approved for clinical use in humans.